2024 saw continued scientific breakthrough and regulatory transformation, and a growing focus on AI and cost containment. Here, those actively supporting the life sciences sector share their reflections on the year just passed, and their hopes and predictions for 12 months ahead.
This year, the ACS GCI Pharmaceutical Roundtable, a leading forum of global pharmaceutical and allied industries, celebrates its 20th year advancing the sustainability of manufacturing medicines through the implementation of green chemistry & engineering. The Roundtable’s impact has been identified by member companies as a leading factor contributing to sustainability strategies for the synthesis of active pharmaceutical ingredients (APIs). Successful strategies to catalyze green chemistry include, i) driving academic research in key areas through the GCIPR grants program, 2) developing a suite of tools and metrics standardized across the industry and open to the public, 3) advancing learning opportunities through accessible online courses and in person training, as well as regular participation in scientific fora. The Roundtable’s global membership ensures best practices are widely distributed and member companies across the supply chain can contribute to effective solutions.
On January 24, 2005, a unique global collaboration was launched between members of the pharmaceutical industry and the American Chemical Society (ACS) Green Chemistry Institute (GCI) to catalyze green chemistry and engineering throughout the global pharmaceutical industry—the ACS GCI Pharmaceutical Roundtable.
The clinical adoption of cell and gene therapies remains primarily focused on rare diseases and patient populations for whom conventional treatments have failed. Despite significant advancements in demonstrating clinically meaningful responses, these therapies are hindered by high manufacturing costs, complex cold chain logistics, and intricate post-treatment care. This review identifies where implementation of specific use-cases for artificial intelligence and robotic automation can address the highest impact challenges for reducing costs and streamlining processes.
The Supply Chain refers to the entire network of entities, resources, activities, and technologies involved in the creation and sale of a product, from the sourcing of starting materials from the supplier to the manufacturer, through to its eventual delivery to the end user.
Just-in-time has been, for a long time, the most successful supply chain model for maximizing efficiency. But, currently, it’s no longer the best.
Especially, today after the pandemic experience companies ask for resilient supply chains to always guarantee their shipments.
Inside this global scenario, in terms of the Supply chain, pharmaceutical companies represent one of the most complex cases, both for the laws and requirements needed and for the characteristics of the goods. Precisely for these reason, the pursuit of its optimization must be a common goal because transforming the pharmaceutical supply chain and adopting sustainable and a reliable approach can help ensure efficient and timely service to patients, reducing inequalities and improving quality of life.
Three in five life science regulatory professionals are now experiencing an increase in day-to-day work throughput that far exceeds what would be expected with company growth. A new survey of senior regulatory professionals at US pharma/biopharma organisations identifies a direct correlation with planned AI investment – now seen as their best bet to stay on top of escalating workloads. Yet closer analysis also reveals that attitudes to AI’s suitability in a regulatory context may need updating. ArisGlobal’s Agnes Cwienczek unpacks the findings.
The biopharmaceutical industry stands at a pivotal crossroads where digital transformation is no longer optional but essential for maintaining competitive edge and ensuring product quality. This article examines how leading manufacturers are leveraging advanced digital technologies to revolutionize their operations and drive unprecedented levels of process control and product consistency. Artificial intelligence and machine learning are reshaping quality control paradigms and enabling predictive maintenance strategies that minimize downtime and optimize resource utilization.
While the potential of digital transformation is immense, organizations face challenges in workforce development and regulatory compliance. The present article provides insight into building robust digital infrastructure while navigating complex regulatory requirements, with focus on recent developments in real-time release testing and continuous process verification.
Please download the PDF here and read it! As part of its
Business continuity in the production of Active Pharmaceutical Ingredients (APIs) is crucial for the
As the U.S. enters a new Trump administration, international companies in the specialty chemical
Seladelpar, marketed under the brand name Livdelzi, is a medication recently approved by the
